A dialysis turnaround tested by a patient referral misstep
- FMS is the world leader in kidney dialysis products and services.
- An internal operational miss in capturing U.S. patient referrals caused a 0.9 percent decline in second quarter same-market treatments.
- The Value-Based Care segment remains a bright spot, generating a EUR 18 million operating profit in the second quarter of 2026.
- The 5008X machine rollout is pacing well with 227 clinics converted by late July 2026.
- Earnings face a steep second half test as temporary Medicare add-on payments fade.
Turnaround progress meets referral stumble
The bull case relies on cost cuts and the Value-Based Care segment. The risk-based care business generated a EUR 18 million operating profit in the second quarter of 2026, proving the model can work. The FME25+ savings program is also delivering ahead of plan, and the 5008X machine rollout reached 10 percent of the U.S. machine base by late July.
The bear case focuses on volume and execution. In the second quarter, an internal misstep in capturing U.S. patient referrals drove a 0.9 percent decline in same-market treatment growth. Management expects growth to languish around this lower level for the rest of 2026.
The second half of 2026 brings steep regulatory tests. A temporary Medicare add-on payment called TDAPA phases out, creating an estimated EUR 50 million drag on earnings. Changes to ACA premium subsidies will also pressure patient affordability, making the referral execution gap harder to absorb.
Clinics plus the tools
FMS is vertically integrated. That means it treats patients in its own dialysis clinics, manages some patients under risk-based contracts, and also makes the machines and supplies used in dialysis.
Care Delivery is the clinic business. It earns money when patients receive dialysis treatments, but it is exposed to wage inflation, staffing shortages, missed referrals, and changes in reimbursement from Medicare, Medicaid, and commercial insurers.
Care Enablement is the product business. It sells hemodialysis machines, peritoneal dialysis cyclers, dialyzers, bloodlines, solutions, and renal drugs. It also supplies the company own clinics, so reported segment revenue includes sales that are later eliminated at the group level.
Value-Based Care manages patients under contracts where FMS can share in savings if care is better and cheaper. This segment achieved a EUR 18 million operating profit in the second quarter of 2026, marking a successful pivot from its historical losses.
Dialysis at scale
Dialysis clinics
The clinic network is the core business. It treats patients through thousands of sites, but FMS is pruning the base by closing weaker locations.
5008X CAREsystem
The 5008X is the main U.S. upgrade cycle. FMS reached 10 percent of its U.S. machine base by late July 2026 and targets a full replacement by the end of 2030.
Hemodialysis machines and dialyzers
These are the core tools for in-center dialysis. Care Enablement sees positive pricing outside China, but China procurement rules remain a drag.
Peritoneal dialysis cyclers and supplies
These products support home-based dialysis. FMS is expanding digital tools like kinexus for remote therapy management.
Value-Based Care contracts
This is a care management business. It adds profit when FMS lowers total medical costs for kidney patients while meeting quality goals.
TherapyWise and digital solutions
A newly introduced cloud-based analytics capability designed to provide insights into kidney replacement therapy in hospital settings.
Three pieces, one kidney focus
Segment mix uses fiscal 2025 segment revenue before inter-segment eliminations from the 2025 Form 20-F. Care Delivery is the largest piece, while Value-Based Care is a smaller but growing standalone segment.
What could break
U.S. referral execution gap
High impact · High oddsFMS relies on a steady flow of patient referrals to fill its clinics. An internal execution miss in capturing U.S. referrals drove a 0.9 percent decline in second quarter same-market treatments. Management expects growth to languish around this level for the rest of 2026.
TDAPA cliff in H2 2026
High impact · High oddsTDAPA is a temporary Medicare add-on payment for certain dialysis drugs. It helped early 2026 earnings, but the phase-out creates a steep second half headwind estimated at EUR 50 million. This transition will test the underlying profitability of the clinic network.
ACA coverage drop-off
High impact · Medium oddsThe OBBBA limits ACA premium tax credit availability. Management expects affordability pressure to create a material headwind as grace periods end. If patients lose coverage or delay care, FMS can lose treatments and face a worse payor mix.
China procurement pressure
Medium impact · High oddsChina volume-based procurement rules push down prices for some healthcare products. FMS expects a headwind from China procurement and related policies to offset better product volume and pricing in other regions.
Middle East logistics cost inflation
Medium impact · Medium oddsConflict in the Middle East is driving raw material and logistics cost inflation. If these pressures breach the guidance range and persist, the Care Enablement segment could see margin erosion.
Third-party cyber failure
Medium impact · Medium oddsFMS depends on outside service providers for parts of its operations. A cyberattack at a vendor could disrupt billing, patient data, or clinic workflows. The risk matters because dialysis is time-sensitive care.
In one breath
What does Fresenius Medical Care do?
FMS treats people with kidney failure through dialysis clinics. It also makes dialysis machines, dialyzers, peritoneal dialysis products, renal drugs, and related healthcare products.
Why does the 5008X matter?
The 5008X is the company new hemodiafiltration system for the U.S. market. FMS wants it to reduce missed treatments and improve outcomes, and it plans to replace its entire clinic installed base by the end of 2030.
What is Value-Based Care at FMS?
Value-Based Care means FMS manages groups of kidney patients under contracts tied to total medical cost and quality. It can earn more if care is better and cheaper, but it can lose money if medical costs run above expectations.
What is the main risk for FMS in 2026?
The main risk is flat or declining U.S. treatment volumes due to referral execution gaps. Lower volumes give FMS less room to absorb the fade in Medicare add-on payments and changes to ACA subsidies.
